Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

Cited In for PubMed (Select 16242838)

1.

Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.

Albaugh P, Fan Y, Mi Y, Sun F, Adrian F, Li N, Jia Y, Sarkisova Y, Kreusch A, Hood T, Lu M, Liu G, Huang S, Liu Z, Loren J, Tuntland T, Karanewsky DS, Seidel HM, Molteni V.

ACS Med Chem Lett. 2012 Jan 1;3(2):140-5. doi: 10.1021/ml200261d. eCollection 2012 Feb 9.

2.

The integrated landscape of driver genomic alterations in glioblastoma.

Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy A, Gupta G, Pisapia DJ, Canoll P, Bruce JN, McLendon RE, Yan H, Aldape K, Finocchiaro G, Mikkelsen T, Privé GG, Bigner DD, Lasorella A, Rabadan R, Iavarone A.

Nat Genet. 2013 Oct;45(10):1141-9. doi: 10.1038/ng.2734. Epub 2013 Aug 5.

3.

Aiding and abetting cancer: mRNA export and the nuclear pore.

Culjkovic-Kraljacic B, Borden KL.

Trends Cell Biol. 2013 Jul;23(7):328-35. doi: 10.1016/j.tcb.2013.03.004. Epub 2013 Apr 10. Review.

4.

Papillary thyroid cancer and inflammatory bowel disease: is there a relationship?

Sonu IS, Blonski W, Lin MV, Lewis J, Aberra F, Lichtenstein GR.

World J Gastroenterol. 2013 Feb 21;19(7):1079-84. doi: 10.3748/wjg.v19.i7.1079.

5.

AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Iyer R, Varela CR, Minturn JE, Ho R, Simpson AM, Light JE, Evans AE, Zhao H, Thress K, Brown JL, Brodeur GM.

Cancer Chemother Pharmacol. 2012 Sep;70(3):477-86. doi: 10.1007/s00280-012-1879-x. Epub 2012 May 24.

6.

Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.

Weiss GJ, Hidalgo M, Borad MJ, Laheru D, Tibes R, Ramanathan RK, Blaydorn L, Jameson G, Jimeno A, Isaacs JD, Scaburri A, Pacciarini MA, Fiorentini F, Ciomei M, Von Hoff DD.

Invest New Drugs. 2012 Dec;30(6):2334-43. doi: 10.1007/s10637-011-9774-6. Epub 2011 Dec 9.

7.

A 6-gene signature identifies four molecular subgroups of neuroblastoma.

Abel F, Dalevi D, Nethander M, Jörnsten R, De Preter K, Vermeulen J, Stallings R, Kogner P, Maris J, Nilsson S.

Cancer Cell Int. 2011 Apr 14;11:9. doi: 10.1186/1475-2867-11-9.

8.

Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies.

Bonora E, Tallini G, Romeo G.

J Oncol. 2010;2010:385206. doi: 10.1155/2010/385206. Epub 2010 Jun 10.

9.

A novel HSP90 modulator with selective activity against thyroid cancers in vitro.

Samadi A, Loo P, Mukerji R, O'Donnell G, Tong X, Timmermann BN, Cohen MS.

Surgery. 2009 Dec;146(6):1196-207. doi: 10.1016/j.surg.2009.09.028.

10.

Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas.

Pita JM, Banito A, Cavaco BM, Leite V.

Br J Cancer. 2009 Nov 17;101(10):1782-91. doi: 10.1038/sj.bjc.6605340. Epub 2009 Oct 6.

12.

On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology.

Thiele CJ, Li Z, McKee AE.

Clin Cancer Res. 2009 Oct 1;15(19):5962-7. doi: 10.1158/1078-0432.CCR-08-0651. Epub 2009 Sep 15. Review.

13.

Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma.

Vasudevan SA, Shang X, Chang S, Ge N, Diaz-Miron JL, Russell HV, Hicks MJ, Ludwig AD, Wesson CL, Burlingame SM, Kim ES, Khan J, Yang J, Nuchtern JG.

Mol Cancer Ther. 2009 Aug;8(8):2478-89. doi: 10.1158/1535-7163.MCT-08-1132. Epub 2009 Aug 11. Erratum in: Mol Cancer Ther. 2009 Sep;8(9):2771. Shang, Xiaoyi [corrected to Shang, Xiaoying].

14.

Nuclear pore proteins and cancer.

Xu S, Powers MA.

Semin Cell Dev Biol. 2009 Jul;20(5):620-30. doi: 10.1016/j.semcdb.2009.03.003. Epub 2009 Mar 18. Review.

15.

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, Sekeres M, Saunthararajah Y, Maciejewski JP.

Blood. 2009 Feb 5;113(6):1315-25. doi: 10.1182/blood-2008-06-163246. Epub 2008 Oct 2.

16.

TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma.

Negri T, Tamborini E, Dagrada GP, Greco A, Staurengo S, Guzzo M, Locati LD, Carbone A, Pierotti MA, Licitra L, Pilotti S.

Transl Oncol. 2008 Sep;1(3):121-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk